Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OPRX
BuyUnloved QualityFLAGOptimizeRx Corporation · Healthcare · United States · $150M · Avg Vol: $2M/d
OptimizeRx has quality Q68 and value V75, but momentum at M32 is well below the calibrated floor, so stage one fails.
COMPANY DESCRIPTION
OptimizeRx Corporation is a digital health technology company that connects pharmaceutical manufacturers with healthcare providers and patients at the point of care. The company's platform integrates directly into electronic health record (EHR) and e-prescribing workflows, creating a high-barrier-to-entry distribution network. Its competitive moat lies in its ability to deliver targeted clinical and financial information to physicians in real time.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.5M | 71.5M | 92.1M | 109.4M | 20.6% | 98.7M | 96.6M | 107.6M | -0.8% |
| EPS | -0.64 | -1.03 | -1.10 | 0.28 | — | 0.25 | 0.24 | 0.28 | 0.4% |
| Shares | 17.1M | 18.2M | 18.5M | 18.8M | +9.9% | 18.8M | — | — | — |
| Debt | 0.2M | 36.8M | 33.2M | 26.1M | 381.1% | 19.5M | — | — | — |
| Equity | 126.1M | 126.6M | 117.0M | 128.3M | 0.6% | — | — | — | — |
| Op CF | 10.7M | -7.2M | 4.9M | 18.7M | 20.7% | 18.4M | — | — | — |
| Inv CF | -58.2M | -25.3M | -0.5M | 68.0K | — | — | — | — | — |
| Fin CF | -19.0M | 28.2M | -4.9M | -8.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OPRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OPRX | OptimizeRx Corporation(you) | $150M | 77 | Buy |
| CCLD | CareCloud, Inc. | $106M | 77 | Buy |
| AMWL | American Well Corporation | $203M | 75 | Buy |
| NURS.V | Hydreight Technologies Inc. | $147M | 59 | Hold |
| SPOK | Spok Holdings, Inc. | $223M | 90 | Strong Buy |
| SLP | Simulations Plus, Inc. | $372M | 83 | Strong Buy |
| NRC | NRC Health | $483M | 73 | Buy |
| WEAV | Weave Communications, Inc. | $583M | 64 | Hold |
| CTEV | Claritev Corporation | $668M | 66 | Buy |
| GDRX | GoodRx Holdings, Inc. | $1.2B | 77 | Buy |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%